Fountain Life continues mission to transform healthcare with new center openings
The world's leading science-backed longevity membership is opening its newest wellness center location in Houston, Texas
HOUSTON, March 25, 2025 /PRNewswire/ -- Fountain Life, the leading science-backed longevity company committed to proactive and data-driven global health care, today announced the scheduled October 2025 opening of its fifth precision diagnostic center, designed to help members achieve optimal health, in Houston, Texas.
Fountain Life uses groundbreaking technology to offer AI-driven diagnostics, personalized health plans, and a dedicated support team, alongside advanced therapeutics that help detect potential illnesses such as cancer, cardiac issues, metabolic disorders, and neurodegenerative diseases. Their proactive approach has identified potentially life-threatening conditions in 14% of seemingly healthy members, and thanks to early detection, these conditions are now fully actionable.
"Our world is undergoing a healthspan revolution, and at Fountain Life, we are at the forefront of unlocking deeper insights into the human body," said William Kapp, MD, CEO of Fountain Life. "Advances in AI, genomics, gene therapy, and cellular medicine are revealing the secrets of aging—empowering us to slow, stop, and even reverse its effects—and our next step is introducing these opportunities to the Houston community."
With existing state-of-the-art centers in Florida, Texas, and New York, the new Houston center is the second location opening in Texas, driven by the popularity of the Dallas center. The center will be located in the acclaimed Park House Houston building, home to a dynamic array of social experiences, culinary offerings, fine art, cultural events and more.
"At Park House, our mission is to provide members with exceptional experiences that enhance their well-being and quality of life," said Brady Wood, CEO of Woodhouse and Co-Founder, Co-Operator of Park House. "With Fountain Life opening within our building, we're bringing cutting-edge preventative health directly to our community, ensuring our members have access to the best resources to live longer, healthier lives."
As interest for wellness solutions continues to grow globally, Fountain Life has future plans to expand even further.
"Experts predict that this decade's medical breakthroughs could extend our health span by decades. Our mission is to ensure our members worldwide stay healthy and fully benefit from these longevity advancements," said Kapp. "We are only at the beginning of the journey."
For more information on Fountain Life and its membership options, visit www.fountainlife.com.
About Fountain LifeFountain Life is the world's leading science-backed longevity center, powered by AI. They bring together a dedicated team of longevity physicians, health coaches, and nutritionists with AI-powered diagnostics to identify and treat life-threatening diseases early, devise personalized health optimization plans, and provide 24/7 concierge medical care. Additionally, Fountain Life members have access to cutting-edge regenerative therapies designed to combat the effects of aging. We invite you to learn more at www.fountainlife.com.
About WoodhouseWoodHouse is an experiential hospitality operator and developer specializing in luxury social clubs, fine dining, and cultural destinations. WoodHouse owns and operates Park House Dallas and Houston, chef-driven Mexican restaurant José, Dior Café by Dominique Crenn in Dallas' Highland Park Village, Citizen House Oklahoma City, Elevation Hotel & Spa in Crested Butte, Pilgrimage Music Festival, and The Moore Miami, a luxury private members club, workspace, and hotel in the Miami Design District.
For more information, visit www.woodhouseus.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fountain-life-continues-mission-to-transform-healthcare-with-new-center-openings-302410781.html
SOURCE Fountain Life
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
SAN DIEGO, June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity. "At Illumina, we work relentlessly in our mission to improve human health by unlocking the power of the genome, and our CSR strategy is an essential part of that," said Jacob Thaysen, CEO of Illumina. "Our innovation has driven incredible breakthroughs—but those breakthroughs only matter if they can be accessed. Our CSR efforts are designed to drive greater access to genomics technologies and improve health equity for billions of people around the world. We continue to take meaningful steps to champion patients, communities, employees, and the planet as we work to create a healthier and more sustainable future." 2024 highlights Making genomics affordable and accessible: Integrating genomics across the care continuum is critical to positive health outcomes, but gaps in health insurance coverage continue to put genomic testing out of reach for many. In 2024, Illumina's advocacy efforts supported the expansion of health care coverage for genomic testing to an additional 100 million people compared to 2023, resulting in a total of 1.4 billion lives covered. Significantly reducing packaging and increasing product sustainability efforts: In 2024, Illumina achieved an 80% reduction in packaging since 2019, surpassing its 2030 target of a 75% reduction. The MiSeq i100 Series, launched in 2024 and designed with sustainability in mind, also achieved a 35% reduction in climate change impact, thanks to its reduced packaging and the room-temperature shipping and storage of its reagents. Operating sustainably: 100% of Illumina's global electricity consumption came from renewable sources for the third consecutive year. Impact areas Illumina's CSR program is rooted in four key areas, and the company's CSR report demonstrates progress made in 2024 in each: Accelerating access to genomics Illumina launched the MiSeq i100 Series, benchtop sequencers designed for faster run times and simplified setup and analysis. Illumina invested in the future of genomics by expanding access to STEM education. The company has reached 2.1 million STEM learners since 2019 through direct programming, nonprofit partners, and employee engagement. Nurturing our people and communities Fifty-two percent of Illumina's employees participated in giving and volunteering programs, donating 91,370 volunteer hours. Illumina maintained a zero net pay gap for the sixth consecutive year. Integrating sustainability Illumina realized a 45% decrease in scopes 1 and 2 emissions from its 2019 baseline. Five Illumina labs completed the eight-month certification process with My Green Lab, the gold standard for laboratory sustainability best practices around the world. Operating responsibly 100% of Illumina's core facilities participated in third-party audit programs. Illumina was named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index (formerly part of the Dow Jones Sustainability Indices) and received a top industry ISS Corporate Governance rating. Illumina continued to exercise strong corporate governance with an independent Board of Directors (all independent with the exception of the CEO) and an independent Board Chair. The full report is available on Illumina's CSR website. About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Contacts Investors:Brian Blanchett+1.858.291.6421ir@ Media:Christine Douglasspr@ View original content to download multimedia: SOURCE Illumina, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025
Full data of Phase 3 REDEFINE 1 and 2 trial results will provide insights on the potential of CagriSema Semaglutide real-world data complements evidence from previous cardiometabolic and kidney outcomes trials Data on pipeline candidate amycretin to underscore Novo Nordisk's scientific efforts to continued innovation in obesity PLAINSBORO, N.J., June 10, 2025 /PRNewswire/ -- Novo Nordisk today announced that new data from its industry-leading cardiometabolic portfolio will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago, June 20 – 23, 2025. A total of 29 abstracts will be presented, including trials investigating the efficacy and safety of CagriSema in people with overweight/obesity (REDEFINE 1) and those with overweight/obesity and type 2 diabetes (REDEFINE 2).1 Further, new data will complement the extensive body of cardiometabolic and kidney evidence for semaglutide in people with type 2 diabetes through analyses of the SOUL, STRIDE and FLOW trials, as well as insights from additional real-world studies in adults with obesity.2-4 "We recognize the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalized treatment approach," said Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. "As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease." The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine. Data will also be presented on pipeline candidate amycretin, demonstrating Novo Nordisk's scientific efforts to deliver innovation in cardiometabolic diseases and individualized healthcare solutions.1 On June 22nd, Novo Nordisk will also host an R&D investor event on our metabolic and cardiovascular health portfolio to cover the science and abstracts presented at the congress. The event will be accessible via a live webcast on the Novo Nordisk investor website. Full details of Novo Nordisk abstracts to be presented at ADA 2025. These data for medicines containing semaglutide, CagriSema, amycretin, insulin icodec, and IcoSema are investigational: ADA Scientific Sessions:
Yahoo
3 hours ago
- Yahoo
ZoomCare Opens New Clinic in Happy Valley
The company will host an Open House for the community on Jun. 13 PORTLAND, Ore., June 10, 2025 /PRNewswire/ -- ZoomCare, a network of neighborhood clinics serving a wide variety of healthcare needs, today announced the opening of a new clinic to serve the community of Happy Valley. The new clinic is located at 17155 SE Sunnyside Road, Suite #160 in the Happy Valley Crossroads Shopping Center. The clinic will be open seven days a week. Staffed with board-certified providers who cater to a broad range of illnesses and injuries, the Happy Valley clinic will also include preventive care services. The location features five exam rooms and offers on-site labs and prescriptions, allowing patients to leave with medications in hand. Since 2006, ZoomCare has been known for its patient experience, which is focused on compassion, quality, and efficiency. "ZoomCare believes you shouldn't have to travel far to receive excellent care," said Jeff Fee, Chief Executive Officer of ZoomCare. "We are thrilled to join the Happy Valley community. Opening this new location aligns perfectly with our mission to make healthcare easy and accessible for everyone." The company will celebrate the new clinic opening with an Open House event on Friday, Jun. 13, from 11 a.m. - 2 p.m. The Open House is open to the public and will offer free specialty coffee drinks and Italian sodas, fun giveaways, and a chance to meet the provider team and see the new clinic space. "This Open House is an excellent opportunity for our providers and clinic staff to get to know the people of Happy Valley," said Jennifer Alemany, Director of Clinical Operations in Portland. "We hope folks will come by, meet our team, and learn more about how ZoomCare can help with their healthcare needs now and in the future!" ZoomCare accepts Medicare and Medicare Advantage at all of its 47 locations in Oregon and Washington. Using Medicare-certified software platform Athenahealth, ZoomCare can access and share electronic health records with other providers and health systems. This certified software platform also lets ZoomCare establish partnerships with large health systems and insurance plans to increase patient access to primary, urgent, emergency, and specialty care. About ZoomCareZoomCare's vision is to make healthcare easy. Founded in 2006 in Portland, Oregon, ZoomCare operates more than 47 urgent, primary, emergency care, and specialty locations throughout Oregon and Washington. With conveniently located neighborhood clinics, plus evening and weekend hours, ZoomCare is committed to providing better access to healthcare and delivering evidence-based care with kindness at every visit. For more information, visit Follow ZoomCare on Facebook, Instagram, LinkedIn, and X. Media ContactAmanda Gibbs Director of Communications agibbs@ View original content to download multimedia: SOURCE ZoomCare
